Clinical Trial is Now Enrolling
“NMIBC continues to be challenging because of frequent disease relapse and patients have limited available treatment options. Patients with Intermediate-Risk NMIBC have been underserved especially since the global BCG shortage. PIVOT-006 is a step in the right direction that aims to address this unmet need and help our patients. I hope that many other Urologists will be interested in this study.”
– Robert Svatek , M.D., MSCI UT Health San Antonio
Lead Investigator
PIVOT-006 is a Phase 3, randomized open-label monotherapy study evaluating cretostimogene grenadenorepvec for the treatment of Intermediate-Risk, Non-Muscle Invasive Bladder Cancer (NMIBC). There are two study arms. One arm is transurethral resection of the bladder (TURBT), or Standard-of-Care in this patient population, and the other arm is TURBT plus cretostimogene. The study endpoint is Recurrence Free Survival.
